Brief: Biosergen Safety Committee Approves To Dose Escalation In Bsg005 Clinical Trial
07/11/2024 07:36
Nov 7 (Reuters) - Biosergen AB BIOSGN.ST :
* SAFETY COMMITTEE APPROVES TO PROCEED WITH DOSE ESCALATION
IN
SECOND COHORT FOR BSG005 CLINICAL TRIAL
Source text: ID:nWkr8qkGmY
Further company coverage: BIOSGN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million